Search tips
Search criteria 


Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1998 November; 66(11): 5357–5363.
PMCID: PMC108670

Helicobacter pylori Lipopolysaccharide Binds to CD14 and Stimulates Release of Interleukin-8, Epithelial Neutrophil-Activating Peptide 78, and Monocyte Chemotactic Protein 1 by Human Monocytes

Editor: J. R. McGhee


Helicobacter pylori gastritis is characterized by leukocyte infiltration of the gastric mucosa. The aims of this study were to determine whether H. pylori-derived factors stimulate chemokine release from human monocytes and to ascertain whether H. pylori lipopolysaccharide (LPS) may be responsible for this effect. Human peripheral blood monocytes were exposed to an H. pylori water extract (HPE) or to purified H. pylori LPS. Levels of the chemokines interleukin-8 (IL-8), epithelial neutrophil-activating peptide 78 (ENA-78), and monocyte chemotactic protein 1 (MCP-1) were measured by enzyme-linked immunosorbent assay. The contribution of H. pylori LPS to monocyte activation was determined by using the LPS antagonist Rhodobacter sphaeroides lipid A (RSLA) and a blocking monoclonal antibody to CD14 (60bca). HPE increased monocyte secretion of IL-8, ENA-78, and MCP-1. Heat treatment of HPE did not reduce its ability to activate monocytes. Purified H. pylori LPS also stimulated monocyte chemokine production but was 1,000-fold less potent than Salmonella minnesota lipid A. RSLA blocked H. pylori LPS-induced monocyte IL-8 release in a dose-dependent fashion (maximal inhibition 82%, P < 0.001). RSLA also inhibited HPE-induced IL-8 release (by 93%, P < 0.001). The anti-CD14 monoclonal antibody 60bca substantially inhibited IL-8 release from HPE-stimulated monocytes (by 88%, P < 0.01), whereas the nonblocking anti-CD14 monoclonal antibody did not. These experiments with potent and specific LPS inhibitors indicate that the main monocyte-stimulating factor in HPE is LPS. H. pylori LPS, acting through CD14, stimulates human monocytes to release the neutrophil-activating chemokines IL-8 and ENA-78 and the monocyte-activating chemokine MCP-1. Despite its low relative potency, H. pylori LPS may play an important role in the pathogenesis of H. pylori gastritis.

Helicobacter pylori is estimated to infect over one-half of the world’s population (4). Although most infections are asymptomatic, H. pylori is associated with the development of gastric and duodenal ulcers, gastric carcinoma, and gastric lymphoma (24, 10). All individuals with H. pylori infection have gastritis, usually involving the antrum, that is characterized by inflammatory cell infiltration with polymorphonuclear cell invasion of the gastric lamina propria and glandular epithelium (10, 11, 20).

The pathophysiologic mechanisms leading to neutrophil infiltration in H. pylori gastritis have been the subject of intense investigation (11, 20, 27). H. pylori is minimally invasive; for this reason most investigators have focused on soluble factors, of either host or bacterial origin, which may mediate neutrophil recruitment. Host factors include proinflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor (TNF), and IL-8, all of which are increased in the antral mucosae of individuals with H. pylori gastritis (15, 21, 23, 40).

Chemokines are a superfamily of closely related chemoattractant cytokines which specialize in mobilizing leukocytes to areas of immune challenge (7, 8, 49). These inducible proinflammatory peptides potently stimulate leukocyte migration along a chemotactic gradient. They also modulate leukocyte adhesion molecule expression and other leukocyte functions that are necessary for leukocytes to leave the circulation and infiltrate tissues. Thus, increased chemokine production and release is an important mechanism for leukocyte recruitment in response to injury or infection. Chemokines are divided into groups or families that are defined by characteristic cysteine motifs. Four families of chemokines—C-X-C, C-C, C, and C-X3-C—have now been described, where C is a conserved cysteine residue and X is any other amino acid (7, 8, 49). IL-8 and epithelial neutrophil-activating peptide 78 (ENA-78) are C-X-C chemokines; both activate neutrophils, and both carry a common ELR (Glu-Leu-Arg) amino acid motif immediately adjacent to their C-X-C sites (8). Monocyte chemotactic protein 1 (MCP-1) is a C-C chemokine that stimulates mononuclear leukocytes.

IL-8 levels are increased in H. pylori gastritis, and a number of studies have demonstrated transcriptional upregulation of IL-8 production by H. pylori-infected gastric epithelial cells (1315, 17, 21, 23, 37, 40, 48). Monocytes and macrophages are another major source of IL-8 production, and the present study focuses on the ability of water-soluble factor release by H. pylori to activate the production of IL-8 and other chemokines by human monocytes. Monocytes are also an important source of IL-1 and TNF, which activate endothelial-cell adhesion molecule expression and thereby cooperate with chemokines such as IL-8 in regulating neutrophil diapedesis (25, 41).

A number of soluble factors released by H. pylori, including urease and lipopolysaccharide (LPS), activate phagocytic leukocytes (11, 16, 3133, 35). H. pylori LPS is a monocyte chemoattractant and mitogen; it activates monocytes to release reactive oxygen intermediate superoxide anion and upregulates monocyte production of IL-1, TNF, and IL-6 (6, 9, 29, 32, 38, 42). Its effects on neutrophils are less dramatic, but it does prime them to respond to other stimuli (39). Despite this wide range of activity, H. pylori LPS is of low potency compared to the LPS produced by gram-negative bacteria of the Enterobacteriaceae family, such as Escherichia coli or Salmonella species (9, 18, 19, 3436, 38, 39, 42). This has led to the hypothesis that H. pylori has evolved to produce a less-inflammatory LPS to facilitate chronic, indolent infection of its host.

The goals of this study were (i) to determine whether water-soluble factors released by H. pylori could activate the release of chemokines, including IL-8, from human monocytes; (ii) to determine whether H. pylori water-soluble factors could upregulate adhesion molecule expression by human endothelial cells; and (iii) to determine the contribution of H. pylori LPS to monocyte and/or endothelial cell activation. To address the first goal, we examined the release of the neutrophil-activating, C-X-C chemokines IL-8 and ENA-78 and the monocyte-activating C-C chemokine MCP-1 from isolated human peripheral blood monocytes exposed to H. pylori water extract. To address the second goal, we examined the surface expression of the leukocyte adhesion receptor ICAM-1 (intracellular adhesion molecule 1) by human endothelial cells after exposure to the same H. pylori water extract. To address the final goal, we used the potent and specific LPS antagonist Rhodobacter sphaeroides, as well as monoclonal antibodies directed against the CD14 LPS receptor. We found that H. pylori water extract activates chemokine release from monocytes but does not upregulate ICAM-1 expression in endothelial cells. Furthermore, our results indicate that, despite its low relative potency, LPS is the main water-soluble H. pylori factor activating monocyte chemokine release in vitro.


H. pylori preparations.

H. pylori 43504 (American Type Culture Collection, Manassas, Va.) was plated on Campylobacter agar with Skirrow’s supplements (Difco, Detroit, Mich.), reconstituted in pyrogen-free water (Baxter, Deerfield, Ill.), supplemented with 10% defibrinated sheep blood (BBL; Becton Dickinson Microbiology, Cockeysville, Md.), and incubated at 37°C in a microaerophilic environment (23). After 3 to 7 days bacteria were harvested by using 1 ml of pyrogen-free Dulbecco’s phosphate-buffered saline (PBS; Cellgro; Mediatech, Herndon, Va.) and sterile cotton swabs. After a thorough mixing, the bacterial suspension was adjusted to an optical density at 600 nm (OD600) of 1.5, a value corresponding to 3.6 × 108 CFU/ml. Bacteria were then pelleted by centrifugation at 4,000 × g for 10 min and again suspended in PBS to an OD600 of 1.5. After 20 min at room temperature, the bacteria were pelleted at 4,000 × g for 10 min. The supernatant was removed and clarified by further centrifugation in a Microfuge-E (Beckman, Palo Alto, Calif.) for 10 min. The supernatant was then filtered through a 0.2-μm (pore size) filter (Acrodisc; Gelman, Ann Arbor, Mich.). The resulting H. pylori extract (HPE) was stored in pyrogen-free polycarbonate tubes (Falcon; Becton Dickinson Labware, Lincoln Park, N.J.) at −70°C until needed. The HPE stock was diluted in PBS for subsequent experiments. The protein content of HPE varied between 0 (undetectable) and 130 μg/ml, as determined by the bicinchoninic acid assay. However, the monocyte-activating potencies of HPE preparations did not correlate with their protein contents and the HPE concentration is therefore expressed as a volume/volume percentage of the stock HPE.

H. pylori LPS, prepared by the cold magnesium-ethyl alcohol method, was kindly provided by Richard Darveau, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Wash. (18, 19).

Chemokine assays.

Levels of the chemokines IL-8, ENA-78, and MCP-1 in monocyte-conditioned media were measured by double-ligand enzyme-linked immunosorbent assay (ELISA) (23, 24, 26). For the IL-8 ELISA, the wells of an Immulon II, 96-well microtiter plate (Dynatech, Chantilly, Va.) were coated with goat anti-human IL-8 antibody (R & D Systems, Minneapolis, Minn.), at 5 μg/ml in 100 μl of carbonate coating buffer (35 mM NaHCO3, 15 mM Na2CO3 [pH 9.6]) and incubated overnight at 4°C. The wells were washed with PBS containing 0.05% Tween 20 (pH 7.0) (PBS-Tween) between each incubation step. Wells were blocked with 2% bovine serum albumin (Sigma, St. Louis, Mo.) in PBS-Tween for 1 h at 37°C. After being washed, samples and IL-8 standards (R&D Systems) in 100 μl of R10 medium (RPMI 1640; Cellgro) were added and the wells were incubated at 37°C for 1 h. Biotin-labeled anti-IL-8, at 2 μg/ml in 100 μl of 2% bovine serum albumin–PBS-Tween, was then added to the wells, and the wells were incubated at 37°C for 1 h. The anti-IL-8 was biotin-labeled by using NHS-LC biotin (Pierce, Rockford, Ill.) according to the manufacturer’s instructions. After being washed, streptavidin-biotin-horseradish peroxidase complex (Pierce), diluted 1:1,000 in PBS-Tween, was added and then the wells were incubated for 30 min at 37°C. After another careful washing with PBS-Tween, 100 μl of tetramethylbenzidine substrate solution (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) was added to each well, and the reaction was stopped after 5 min with 100 μl of 1 M o-phosphoric acid. The OD490 was determined with an automated microplate photometer (Dynatech), and the concentrations of IL-8 were determined by comparison with the IL-8 standard curve. The IL-8 ELISA showed no cross-reactivity with a panel of other cytokines and chemokines and had a sensitivity of <50 pg of IL-8/ml.

The ENA-78 and MCP-1 assays followed a method similar to that used for the IL-8 ELISA except that Maxisorb plates (Nunc, Naperville, Ill.) were used. For the ENA-78 ELISA, plates were coated with goat anti-ENA-78 (R&D Systems), and biotin-labeled goat anti-ENA-78 was used as the secondary antibody. For the MCP-1 ELISA plates were coated with goat anti-MCP-1 (R&D Systems). Rabbit anti-MCP-1 (Genzyme, Cambridge, Mass.) was used as the secondary antibody, followed by biotinylated donkey anti-rabbit immunoglobulin G (IgG) (1:1,000; Amersham). Human recombinant ENA-78 and MCP-1 were used as standards (R&D Systems). Both assays showed a sensitivity of <50 pg/ml.

Isolation and stimulation of peripheral blood monocytes.

Peripheral blood mononuclear cells were isolated from heparinized peripheral venous blood obtained from healthy volunteers by using lymphocyte separation media (OrganonTeknika, Durham, N.C.) as previously described (28, 30). The peripheral blood mononuclear cells were washed three times with Hank’s balanced salt solution (Cellgro) and plated on 96-well plastic culture dishes at a density of 5 × 104 cells per well in 100 μl of RPMI supplemented with heat-inactivated 10% fetal calf serum (HyClone, Logan, Utah), 2 mM glutamine, 5 mM HEPES, 100 U of penicillin per ml, and 100 μg of streptomycin per ml (all from Sigma). After 90 min the nonadherent lymphocytes were removed by washing. Monocyte purity, determined by nonspecific esterase staining, was greater than 90%. Monocytes were rested by overnight incubation prior to performing stimulation experiments.

The agents added to the monocyte culture medium to determine their ability to stimulate chemokine production by human monocytes included HPE, H. pylori LPS, E. coli LPS (E. coli O55:B5 LPS; Sigma), and lipid A of the deep rough mutant of Salmonella minnesota R595 (a gift from Nilo Qureshi, University of Wisconsin). For time course experiments the monocytes were exposed to HPE for 2 h. The conditioned medium was then harvested and replaced with fresh medium at each time point.

Cell-ELISA for ICAM-1 expression by human endothelial cells.

Early-passage human endothelial cells (EndoPack-UV; Clonetics, San Diego, Calif.) were grown to confluence on 96-well tissue culture plates. Endothelial monolayers were incubated with R10 medium (control), IL-1β (positive control), H. pylori LPS, HPE, or monocyte conditioned media. After overnight incubation the endothelial monolayers were fixed with 1% paraformaldehyde, and the ICAM-1 surface expression was measured with a cell-ELISA (26, 28). The primary antibody for this ELISA is RR1/1, a mouse IgG1 monoclonal antibody directed against human ICAM-1, generously provided by R. Rothlein (Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn.) and T. A. Springer (Center for Blood research, Harvard Medical School, Boston, Mass.).

Inhibition of LPS effects by using R. sphaeroides lipid A and anti-CD14.

In some experiments the LPS antagonist B287 (Eisai Institute, Andover, Mass.) was added prior to monocyte stimulation (22, 47). B287 is a synthetic compound whose structure is identical to the proposed structure of R. sphaeroides lipid A (RSLA) (12, 22, 47). In other experiments a blocking anti-CD14 monoclonal antibody, 60bca (10 μg/ml), was added prior to the addition of stimuli (51). A monoclonal antibody, 26iC (10 μg/ml), which recognizes CD14 but does not block LPS binding to CD14, was used as a control. These anti-CD14 monoclonal antibodies were prepared from ATCC clones 60bca and 26iC by John Schreiber, Rainbow Babies Children’s Hospital, Cleveland, Ohio. Medium supplemented with 2% human serum was used for all of the experiments with the anti-CD14 antibodies since fetal calf serum contains substantial amounts of soluble CD14. Monocytes were incubated with each of the different stimuli at 37°C for 6 h unless otherwise specified. The monocyte conditioned media were then harvested, and cytokine levels were measured by ELISA.

Statistical analyses.

Statistical analyses were performed by using SigmaStat for Windows version 2.0 (Jandel Scientific Software, San Rafael, Calif.). Unless stated otherwise, analysis of variance followed by protected t tests was used for the intergroup comparisons. A P value of <0.05 was considered statistically significant.


HPE stimulates chemokine release from human monocytes.

HPE, which contains water-soluble factors released from H. pylori, activated the release of the chemotactic cytokines IL-8, MCP-1, and ENA-78 from human monocytes. Stimulation of IL-8 release from monocytes by HPE was dose dependent (Fig. (Fig.1).1). Significant monocyte stimulation was evident with concentrations of HPE of 0.06% or greater. In time course experiments, monocytes exposed to 1% HPE showed a marked increase in IL-8 release within 2 h compared to control monocytes, and increased IL-8 release was sustained for at least 24 h (data not shown). HPE also caused a dose-dependent increase in the production of the chemokines MCP-1 (Fig. (Fig.2)2) and ENA-78 (data not shown) by human monocytes.

FIG. 1
HPE stimulates IL-8 production by human monocytes. Human monocytes were exposed to various concentrations of HPE (see Materials and Methods), and IL-8 levels were measured by ELISA in conditioned media harvested after 18 h. In this representative experiment, ...
FIG. 2
HPE stimulates MCP-1 production by human monocytes. Human monocytes were exposed to various concentrations of HPE, and MCP-1 levels were measured by ELISA in conditioned media harvested after 18 h. In this representative experiment, n ≥ 3 for ...

H. pylori LPS stimulates chemokine release from human monocytes.

Purified H. pylori LPS at concentrations of 10 ng/ml or greater caused a significant increase in chemokine release from human monocytes (Fig. (Fig.33 and and4).4). S. minnesota lipid A also caused a dose-dependent increase in chemokine production. As shown in Fig. Fig.4,4, the maximal levels of IL-8 produced after stimulation of monocytes with H. pylori LPS or lipid A were similar. However, as previously reported (9, 18, 19, 34, 36, 38, 39, 42), there was a marked difference in the potencies of the two LPS preparations, and approximately 1,000-fold-higher concentrations of H. pylori LPS were required to achieve the same degree of monocyte activation.

FIG. 3
HPE and H. pylori LPS stimulate ENA-78 production by human monocytes. Human monocytes were exposed to HPE (Hp extract; 10% concentration) or to H. pylori LPS (Hp LPS; 100 ng/ml), and the ENA-78 levels were measured by ELISA in conditioned media ...
FIG. 4
H. pylori LPS has low potency in stimulating monocyte IL-8 release. Human monocytes were exposed to various concentrations of H. pylori LPS or to S. minnesota lipid A, and the IL-8 levels were measured by ELISA in conditioned media harvested after 18 ...

H. pylori LPS does not upregulate endothelial-cell ICAM-1 expression.

Both IL-1β (25 ng/ml) (Fig. (Fig.5)5) and S. minnesota lipid A (1 ng/ml; data not shown) caused a significant increase in endothelial-cell surface ICAM-1. In contrast, neither H. pylori LPS (100 ng/ml) nor HPE (30%) directly upregulated ICAM-1 levels. However, when conditioned medium from HPE-exposed monocytes was added to the endothelial-cell monolayer, it caused a marked increase in endothelial ICAM-1 levels. This effect was not seen with conditioned medium from control, unstimulated monocytes.

FIG. 5
H. pylori LPS and HPE do not directly upregulate endothelial-cell ICAM-1 expression. Human endothelial cells were exposed to IL-1β (25 ng/ml), H. pylori LPS (100 ng/ml), HPE (30% concentration), and to conditioned medium from either control ...

LPS inhibitor RSLA blocks H. pylori extract-stimulated monocyte IL-8 production.

Having demonstrated that HPE activates the release of the chemokines IL-8, ENA-78, and MCP-1 from human monocytes, we then focused on determining the mechanism(s) of this effect. In subsequent experiments we used IL-8 as an “indicator” chemokine, since chemokine secretion by monocytes follows a common pattern of regulation whereby NF-κB-mediated gene activation is quickly followed by increased chemokine protein production and release (7, 8, 23, 24, 49).

We next sought to determine the extent to which H. pylori LPS, present in the H. pylori water extract, was responsible for monocyte stimulation. RSLA is a structural analogue of LPS that acts as a competitive antagonist to S. minnesota lipid A and to the LPS of other gram-negative bacilli. We first determined whether RSLA was an effective inhibitor of H. pylori LPS. As illustrated in Fig. Fig.6,6, RSLA caused a dose-dependent inhibition of IL-8 release by monocytes exposed to H. pylori LPS at 100 ng/ml. RSLA concentrations of 10 and 100 μg/ml reduced H. pylori LPS-stimulated IL-8 production by 85% (P < 0.01). RSLA alone did not cause any significant alteration in IL-8 production by unstimulated monocytes (Fig. (Fig.6).6).

FIG. 6
RSLA blocks the ability of H. pylori LPS to stimulate monocyte IL-8 production. Human monocytes were exposed to various concentrations of RSLA in the presence or absence of H. pylori LPS (100 ng/ml) or S. minnesota lipid A (1 ng/ml). The IL-8 levels were ...

RSLA also blocked HPE-stimulated IL-8 release (Fig. (Fig.7).7). RSLA (1 μg/ml) completely prevented the upregulation of IL-8 release by monocytes exposed to HPE at concentrations of 0.1% and 1%. HPE 10% caused a marked increase in monocyte IL-8 release that was inhibited by 93% in the presence of RSLA (Fig. (Fig.7).7).

FIG. 7
The LPS inhibitor RSLA blocks the ability of HPE to stimulate monocyte IL-8 production. Human monocytes were exposed to various concentrations of HPE alone or with RSLA (1 μg/ml). The IL-8 levels were measured by ELISA in conditioned media harvested ...

Since LPS is heat stable, we also studied whether heating HPE (100°C for 15 min) would alter its ability to stimulate chemokine release by monocytes. Heat treatment did not reduce monocyte activation by HPE (Fig. (Fig.8).8). Furthermore, RSLA blocked monocyte activation by heat-treated HPE to a degree similar to that produced by untreated HPE.

FIG. 8
The monocyte-activating factor in HPE is heat stable. Human monocytes were exposed to HPE (10% concentration) or to the same concentration of heat-treated HPE (100°C for 15 min) in the presence or absence of RSLA (1 μg/ml). The ...

HPE uses the CD14 receptor to stimulate IL-8 production in monocytes.

The data presented above suggest that H. pylori LPS is the principal factor in HPE responsible for increasing monocyte IL-8 release. In order to test this further, we examined whether blocking CD14, the monocyte LPS receptor, by another method would again prevent HPE-mediated monocyte activation. 60bca is a murine monoclonal antibody that binds to CD14 and blocks LPS-CD14 interaction. 26iC is a murine monoclonal antibody which also binds CD14 but does not block CD14-mediated activation by LPS. Neither antibody had a significant effect on IL-8 release by unstimulated monocytes (Fig. (Fig.9).9). 60bca, but not 26iC, blocked monocyte activation by H. pylori LPS (10 μg/ml, 89% inhibition, P < 0.01). 60bca also blocked HPE-stimulated IL-8 release to a similar extent (84% inhibition, P < 0.01).

FIG. 9
The monocyte-activating factor in HPE uses the CD14 receptor. Human monocytes were exposed to S. minnesota lipid A (Sal LA), H. pylori LPS (Hp LPS; 10 μg/ml), or HPE (Hp extract; 10% concentration) alone or in the presence of either 26iC ...


Our studies demonstrate that H. pylori LPS stimulates the release of both neutrophil-activating, C-X-C chemokines (IL-8 and ENA-78) and the monocyte-activating C-C chemokine MCP-1 from human monocytes. These chemokines are potent leukocyte chemoattractants and may play an important role in regulating inflammatory cell infiltration of H. pylori-infected gastric mucosa (7, 11, 14, 15, 20, 21, 23, 27, 37, 40, 48). We found that H. pylori LPS is less potent than Salmonella lipid A in inducing monocyte chemokine production. This finding agrees with previous studies showing low potency for H. pylori LPS in the induction of a wide variety of host inflammatory responses (9, 18, 19, 34, 36, 38, 39, 42). However, when the actions of H. pylori LPS were specifically inhibited by using either an LPS antagonist or CD14 receptor blockade, the monocyte-activating potential of H. pylori water extract was almost completely abolished. These findings suggest that H. pylori LPS may be the primary monocyte-activating factor present in H. pylori water extract.

The monoclonal antibody 60bca binds to CD14 and blocks LPS-CD14 interaction (51). This antibody markedly inhibited activation of human monocytes by both purified H. pylori LPS and H. pylori water extract. The nonblocking anti-CD14 monoclonal antibody 26iC had no significant effect. These findings confirm that H. pylori LPS, in common with LPS from Enterobacteriaceae, activates human monocytes through CD14 receptor binding. This agrees with a recent study demonstrating that CD14 and LPS-binding protein were required for maximal activation of 70Z/3 cells by H. pylori LPS (29). Binding of LPS to CD14 is greatly enhanced by the attachment of LPS binding protein to LPS. Cunningham et al. reported that H. pylori LPS transfers very slowly from LPS binding protein to recombinant soluble CD14 and suggest that this may be an important factor in determining the low biological potency of H. pylori LPS (18).

A number of studies report that gastric mucosal levels of IL-8 are increased in patients with H. pylori gastritis (1315, 21, 23, 37, 52). More recently, increased expression of ENA-78 mRNA was also described in H. pylori infection and appeared to correlate with the severity of gastritis (44). Both IL-8 and ENA-78 are produced by gastrointestinal epithelial cells, as well as by monocytes and macrophages (7, 8, 1315, 17, 23, 24, 48, 49). Activation of epithelial cell IL-8 and ENA-78 production seems to require contact between live H. pylori and the gastric epithelial cell (1, 17, 23, 45). H. pylori LPS shows little activity in stimulating epithelial cells, possibly reflecting their lack of CD14 expression. This is in contrast to human monocytes and macrophages, which highly express CD14. These findings indicate appropriate differentiation of immune responsiveness whereby the gastric epithelial cell responds only to direct contact with H. pylori, whereas lamina propria cells respond to soluble bacterial products which, in vivo, would signal a breach in the integrity of the epithelial barrier.

Chemokines provide a chemoattractant signal to direct neutrophil migration toward an inflammatory focus. However, endothelial cell activation is required also for neutrophils to adhere to the vascular endothelium, migrate between endothelial cell tight junctions, and infiltrate tissues (8, 17, 19, 25, 41). This led us to examine whether HPE could also activate endothelial cells and upregulate their expression of the adhesion molecule ICAM-1. ICAM-1 binds to neutrophil β2 integrin adhesion receptors, a necessary step in neutrophil diapedesis. We find that HPE does not upregulate directly human endothelial cell ICAM-1 expression in vitro. However, activation of monocytes by HPE results in the release of monocyte-derived factors which can increase endothelial cell ICAM-1 expression, thereby facilitating leukocyte infiltration of the gastric lamina propria.

Because of its low potency, H. pylori LPS had been considered to play a minor role in disease pathogenesis. However, it is now known that the O antigen region of H. pylori LPS contains extended chains with N-acetyl-lactosamine units that may mimic the human cell surface glycoconjugates LewisX and LewisY (6, 35, 50). These antigens may act as a cloak to allow H. pylori to escape host immune surveillance. However, antigenic mimicry by H. pylori LPS may also incite an autoimmune response, resulting in gastric mucosal injury (5). H. pylori LPS causes an acute gastritis and results in the induction of gastric epithelial cell apoptosis (43). Another recent study found severe atrophic gastritis in C3H/He mice 6 months after infection with H. pylori. In contrast, no atrophy was found in H. pylori-infected C3H/HeJ mice, which are unresponsive to LPS (46). The main difference observed between the LPS-responsive and nonresponsive mouse strains in this study was a lack of macrophage infiltration of the lamina propria in the latter group. Our studies examined peripheral blood monocytes and may not be directly relevant to gastric lamina propria macrophages. However, our findings suggest that H. pylori LPS is an important virulence factor that plays a key role in CD14-mediated monocyte activation and inflammatory cell recruitment in H. pylori gastritis.


This work was supported by grants DK54920, DK02128, and GM54060 from the National Institutes of Health.

Portions of this work were presented at the 95th and 96th Annual Meetings of the American Gastroenterological Association and were published in abstract form in Gastroenterology in 1995 and 1996 (108:A785 and 110:A867, respectively).


1. Aihara M, Tsuchimoto D, Takizawa H, Azuma A, Wakebe H, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun. 1997;65:3218–3224. [PMC free article] [PubMed]
2. Anonymous. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65–69. [PubMed]
3. Anonymous. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. [PubMed]
4. Anonymous. The report of the Digestive Health Initiative international conference on Helicobacter pylori. Gastroenterology. 1997;113:S1–S169. [PubMed]
5. Appelmelk B J, Negrini R, Moran A P, Kuipers E J. Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol. 1997;5:70–73. [PubMed]
6. Aspinall G O, Monteiro M A, Pang H, Walsh E J, Moran A P. Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): structure of the O antigen chain and core oligosaccharide regions. Biochemistry. 1996;35:2489–2497. [PubMed]
7. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol. 1995;17:103–108. [PubMed]
8. Ben-Baruch A, Michiel D F, Oppenheim J J. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem. 1996;270:11703–11706. [PubMed]
9. Birkholz S, Knipp U, Nietzki C, Adamek R J, Opferkuch W. Immunological activity of lipopolysaccharide of Helicobacter pylori on human peripheral mononuclear blood cells in comparison to lipopolysaccharides of other intestinal bacteria. FEMS Immunol Med Microbiol. 1993;6:317–324. [PubMed]
10. Blaser, M. J. 1995. The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Aliment. Pharmacol. Ther. 9(Suppl. 1):27–30. [PubMed]
11. Calam J. Pathogenic mechanisms. In: Calam J, editor. Helicobacter pylori. London, United Kingdom: Bailliere Tindall; 1995. pp. 487–506.
12. Christ W J, McGuinness P D, Asano O, Wang Y, Mullarkey M A, Perez L, Hawkins T, Blythe T A, Dubuc G R, Robidoux A L. Total synthesis of the proposed structure of Rhodobacter sphaeroides lipid A. J Am Chem Soc. 1994;116:3637–3638.
13. Crabtree J E, Covacci A, Farmery S M, Xiang Z, Tompkins D S, Perry S, Lindley I J, Rappuoli R. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol. 1995;48:41–45. [PMC free article] [PubMed]
14. Crabtree, J. E., and I. J. Lindley. 1994. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. Eur. J. Gastroenterol. Hepatol. 6(Suppl. 1):S33–S38. [PubMed]
15. Crabtree J E, Wyatt J I, Trejdosiewicz L K, Peichl P, Nichols P H, Ramsay N, Primrose J N, Lindley I J. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol. 1994;47:61–66. [PMC free article] [PubMed]
16. Craig P M, Territo M C, Karnes W E, Walsh J H. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils. Gut. 1992;33:1020–1023. [PMC free article] [PubMed]
17. Crowe S E, Alvarez L, Dytoc M, Hunt R H, Muller M, Sherman P, Patel J, Jin Y, Ernst P B. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology. 1995;108:65–74. [PubMed]
18. Cunningham M D, Seachord C, Ratcliffe K, Bainbridge B, Aruffo A, Darveau R P. Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Infect Immun. 1996;64:3601–3608. [PMC free article] [PubMed]
19. Darveau R P, Cunningham M D, Bailey T, Seachord C, Ratcliffe K, Bainbridge B, Dietsch M, Page R C, Aruffo A. Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. Infect Immun. 1995;63:1311–1317. [PMC free article] [PubMed]
20. Ernst P B, Crowe S E, Reyes V E. How does Helicobacter pylori cause mucosal damage? The inflammatory response. Gastroenterology. 1997;113:S35–S42. [PubMed]
21. Fan X G, Chua A, Fan X J, Keeling P W. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol. 1995;48:133–136. [PMC free article] [PubMed]
22. Golenbock D T, Hampton R Y, Qureshi N, Takayama K, Raetz C R. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem. 1991;266:19490–19498. [PubMed]
23. Keates S, Hitti Y S, Upton M, Kelly C P. Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology. 1997;113:1099–1109. [PubMed]
24. Keates S, Keates A C, Mizoguchi E, Bhan A, Kelly C P. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol. 1997;273:G75–G82. [PubMed]
25. Kelly C P. Leukocyte adhesion in gastrointestinal inflammation. In: Walker W A, editor. Current opinion in gastroenterology. Philadelphia, Pa: Current Science; 1993. pp. 962–970.
26. Kelly C P, Keates S, Siegenberg D, Linevsky J K, Pothoulakis C, Brady H R. IL-8 secretion and neutrophil activation by HT-29 colonic epithelial cells. Am J Physiol. 1994;267:G991–G997. [PubMed]
27. Kelly C P, Michetti P. Pathogenesis of Helicobacter pylori infection. In: Boedeker E C, editor. Current opinion in gastroenterology. Philadelphia, Pa: Current Science; 1998. pp. 57–63.
28. Kelly C P, O’Keane J C, Orellana J, Schroy III P C, Yang S, LaMont J T, Brady H R, Schroy P C. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. Am J Physiol. 1992;263:G864–G870. [PubMed]
29. Kirkland T, Viriyakosol S, Perez-Perez G I, Blaser M J. Helicobacter pylori lipopolysaccharide can activate 70Z/3 cells via CD14. Infect Immun. 1997;65:604–608. [PMC free article] [PubMed]
30. Linevsky J K, Pothoulakis C, Keates S, Warny M, Keates A C, LaMont J T, Kelly C P. IL-8 production and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol. 1997;273:G1333–G1340. [PubMed]
31. Mai U E, Perez-Perez G I, Allen J B, Wahl S M, Blaser M J, Smith P D. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med. 1992;175:517–525. [PMC free article] [PubMed]
32. Mai U E, Perez-Perez G I, Wahl L M, Wahl S M, Blaser M J, Smith P D. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Investig. 1991;87:894–900. [PMC free article] [PubMed]
33. Marshall B J. Helicobacter pylori. Am J Gastroenterol. 1994;89:S116–S128. [PubMed]
34. Mattsby-Baltzer I, Mielniczuk Z, Larsson L, Lindgren K, Goodwin S. Lipid A in Helicobacter pylori. Infect Immun. 1992;60:4383–4387. [PMC free article] [PubMed]
35. Mobley H L. Helicobacter pylori factors associated with disease development. Gastroenterology. 1997;113:S21–S28. [PubMed]
36. Moran, A. P. 1996. The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Aliment. Pharmacol. Ther. 10(Suppl. 1):39–50. [PubMed]
37. Moss S F, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori-associated antral gastritis. Gut. 1994;35:1567–1570. [PMC free article] [PubMed]
38. Muotiala A, Helander I M, Pyhala L, Kosunen T U, Moran A P. Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun. 1992;60:1714–1716. [PMC free article] [PubMed]
39. Nielsen H, Birkholz S, Andersen L P, Moran A P. Neutrophil activation by Helicobacter pylori lipopolysaccharides. J Infect Dis. 1994;170:135–139. [PubMed]
40. Noach L A, Bosma N B, Jansen J, Hoek F J, van Deventer S J, Tytgat G N. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol. 1994;29:425–429. [PubMed]
41. Pedersen G, Brynskov J, Nielsen O H, Bendtzen K. Adhesion molecules in inflammatory and neoplastic intestinal diseases. Dig Dis. 1995;13:322–336. [PubMed]
42. Perez-Perez G I, Shepherd V L, Morrow J D, Blaser M J. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun. 1995;63:1183–1187. [PMC free article] [PubMed]
43. Piotrowski J, Piotrowski E, Skrodzka D, Slomiany A, Slomiany B L. Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide. Scand J Gastroenterol. 1997;32:203–211. [PubMed]
44. Rieder G, Einsiedl W, Hatz R A, Walz A, Stolte M, Enders G. The CXC-cytokine ENA-78 correlates strictly with activity of H. pylori-associated gastritis. Gut. 1997;41:A14–A15. . (Abstract.)
45. Rieder G, Hatz R A, Moran A P, Walz A, Stolte M, Enders G. Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis. Infect Immun. 1997;65:3622–3630. [PMC free article] [PubMed]
46. Sakagami T, Vella J, Dixon M F, O’Rourke J, Radcliff F, Sutton P, Shimoyama T, Beagley K, Lee A. The endotoxin of Helicobacter pylori is a modulator of host-dependent gastritis. Infect Immun. 1997;65:3310–3316. [PMC free article] [PubMed]
47. Savedra R, Jr, Delude R L, Ingalls R R, Fenton M J, Golenbock D T. Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J Immunol. 1996;157:2549–2554. [PubMed]
48. Sharma S A, Tummuru M K, Miller G G, Blaser M J. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun. 1995;63:1681–1687. [PMC free article] [PubMed]
49. Taub D D, Oppenheim J J. Chemokines, inflammation and the immune system. Ther Immunol. 1994;1:229–246. [PubMed]
50. Wirth H P, Yang M, Peek R M, Jr, Tham K T, Blaser M J. Helicobacter pylori Lewis expression is related to the host Lewis phenotype. Gastroenterology. 1997;113:1091–1098. [PubMed]
51. Wright S D, Ramos R A, Tobias P S, Ulevitch R J, Mathison J C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–1433. [PubMed]
52. Yoshida N, Granger D N, Evans D J, Jr, Evans D G, Graham D Y, Anderson D C, Wolf R E, Kvietys P R. Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology. 1993;105:1431–1440. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)